Cartesian Therapeutics (RNAC) Gains from Investment Securities (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Gains from Investment Securities of -$94000.0 for Q1 2026, up 94.83% year-over-year from -$48247.3 in Q1 2025, and up 86.7% quarter-over-quarter from -$707000.0 in Q4 2025.
Powered by 
Analysis
Cartesian Therapeutics (RNAC) Gains from Investment Securities (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Gains from Investment Securities for 10 consecutive years, with -$94000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 94.83% year-over-year to -$94000.0; the TTM figure through Mar 2026 stood at -$2.0 million (up 40.88% YoY), while the FY2025 annual figure was -$3.7 million, down 44.45% from the prior year.
- Gains from Investment Securities rose to -$94000.0 in Q1 2026 per RNAC's latest filing, from -$707000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $6.5 million in Q3 2022 and bottomed at -$18.5 million in Q1 2022.
- Historically, Gains from Investment Securities has averaged -$2.4 million across 5 years, with a median of -$707000.0 in 2025.
- Annual changes were most pronounced in 2022 — Gains from Investment Securities jumped 1204.56% — and 2025, when it tumbled 388.57%.
- Cartesian Therapeutics' Gains from Investment Securities stood at -$13.6 million in 2022, then soared by 50.59% to -$6.7 million in 2023, then soared by 103.66% to $245000.0 in 2024, then tumbled by 388.57% to -$707000.0 in 2025, then surged by 86.7% to -$94000.0 in 2026.
- Business Quant data shows RNAC's Gains from Investment Securities at -$94000.0 in Q1 2026, -$707000.0 in Q4 2025, and -$516000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Cartesian Therapeutics | 271.98 Mn | 271.98 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 118,000.00 |
| Mar 31, 2026 | -94,000.00 |
| Dec 31, 2025 | -707,000.00 |
| Sep 30, 2025 | -516,000.00 |
| Jun 30, 2025 | -654,000.00 |
| Mar 31, 2025 | -1.82 Mn |
| Dec 31, 2024 | 245,000.00 |
| Sep 30, 2024 | -5.67 Mn |
| Jun 30, 2024 | 3.91 Mn |
| Mar 31, 2024 | -1.04 Mn |
| Dec 31, 2023 | -6.70 Mn |
| Sep 30, 2023 | -3.79 Mn |
| Jun 30, 2023 | -6.34 Mn |
| Mar 31, 2023 | 4.08 Mn |
| Dec 31, 2022 | -13.55 Mn |
| Sep 30, 2022 | 6.54 Mn |
| Jun 30, 2022 | 4.65 Mn |
| Mar 31, 2022 | -18.52 Mn |
| Dec 31, 2021 | -9.00 Mn |
| Sep 30, 2021 | -592,000.00 |